Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
SG11201701377YA - Compositions and methods to treat vision disorders - Google Patents
[go: Go Back, main page]

SG11201701377YA - Compositions and methods to treat vision disorders - Google Patents

Compositions and methods to treat vision disorders

Info

Publication number
SG11201701377YA
SG11201701377YA SG11201701377YA SG11201701377YA SG11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
vision disorders
treat vision
treat
Prior art date
Application number
SG11201701377YA
Inventor
Kang Zhang
Rui Hou
Original Assignee
Kang Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kang Zhang filed Critical Kang Zhang
Publication of SG11201701377YA publication Critical patent/SG11201701377YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SG11201701377YA 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders SG11201701377YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US201562194120P 2015-07-17 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Publications (1)

Publication Number Publication Date
SG11201701377YA true SG11201701377YA (en) 2017-03-30

Family

ID=55351326

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701377YA SG11201701377YA (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Country Status (13)

Country Link
US (1) US10471076B2 (en)
EP (1) EP3182977B1 (en)
JP (1) JP6706020B2 (en)
KR (1) KR20170048426A (en)
CN (2) CN111529481B (en)
AU (1) AU2015305199A1 (en)
BR (1) BR112017003529A2 (en)
CA (1) CA2958868A1 (en)
EA (1) EA035798B1 (en)
HK (1) HK1243325A1 (en)
MX (1) MX2017002374A (en)
SG (1) SG11201701377YA (en)
WO (1) WO2016029199A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701377YA (en) 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders
JP2018522070A (en) 2015-07-27 2018-08-09 キャタコア・インコーポレイテッドCatacore, Inc. Cataract treatment composition
CN109481392B (en) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 Ophthalmic preparation for preventing and treating cataract and preparation method thereof
CN107397745A (en) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 Azole compounds eye-drops preparations
CN106344587A (en) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 Lanosterol compound preparation for eyes
EP3536698B1 (en) * 2017-01-25 2021-08-04 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Lanosterol prodrug compound and use thereof
US20200281944A1 (en) * 2017-11-17 2020-09-10 Mahmood Piraee Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders
CN109985052A (en) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 The new application of triterpene compound
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
WO2020020306A1 (en) * 2018-07-25 2020-01-30 中山大学中山眼科中心 Crystal form of lanosterol prodrug compound and application thereof
WO2020177714A1 (en) * 2019-03-04 2020-09-10 中山大学中山眼科中心 Composition of lanosterol prodrug compound, preparation method therefor and use thereof
MX2021009520A (en) 2021-08-06 2023-02-07 Foodvica S A De C V Ophthalmic composition for the treatment of visual disorders.
CN115737654B (en) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 Eye drop preparation for preventing and/or treating cataract
CN116832140A (en) * 2022-02-09 2023-10-03 上海瑞吉康生物医药有限公司 Methods of treating cataract using polypeptides
TW202404608A (en) * 2022-04-15 2024-02-01 大陸商廣州潤爾眼科生物科技有限公司 Use of steroid compound in the preparation of drug for preventing and/or treating presbyopia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2009107753A1 (en) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
PT2323666T (en) * 2008-08-05 2017-04-06 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
CA2878946A1 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
MX2015002208A (en) * 2012-08-31 2015-05-08 Bausch & Lomb Ophthalmic compositions with omega-3 fatty acids.
SG11201701377YA (en) 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders

Also Published As

Publication number Publication date
CN111529481B (en) 2023-09-15
EA035798B1 (en) 2020-08-12
HK1243325A1 (en) 2018-07-13
EP3182977A4 (en) 2018-04-11
CN111529481A (en) 2020-08-14
AU2015305199A1 (en) 2017-04-13
US20170065617A1 (en) 2017-03-09
KR20170048426A (en) 2017-05-08
MX2017002374A (en) 2017-09-15
US10471076B2 (en) 2019-11-12
CN107206009B (en) 2020-03-27
JP6706020B2 (en) 2020-06-03
EP3182977A1 (en) 2017-06-28
JP2017525769A (en) 2017-09-07
EP3182977B1 (en) 2021-05-05
BR112017003529A2 (en) 2019-08-20
WO2016029199A1 (en) 2016-02-25
EA201790397A1 (en) 2017-08-31
CN107206009A (en) 2017-09-26
CA2958868A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
SG11201701377YA (en) Compositions and methods to treat vision disorders
IL251066B (en) Compositions and methods of use for treating metabolic disorders
ZA201607540B (en) Compositions and methods to treating hemoglobinopathies
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL246791A0 (en) Compositions and methods for treating ocular diseases
SG10202009859YA (en) Compositions and methods for treating cns disorders
PT3206493T (en) Compositions and methods for treating cns disorders
PT3224269T (en) Compositions and methods for treating cns disorders
IL250715A0 (en) Compositions and methods for treating proliferation disorders
IL247699A0 (en) Compositions and methods for treating kidney disorders
HUE049518T2 (en) Compositions and methods for treating and diagnosing ocular disorders
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3142699A4 (en) Compositions and methods for treating metabolic disorders
SG11201704829QA (en) Methods and compositions for treating brain diseases
IL253220A0 (en) Compositions and methods for treating glaucoma
IL250114B (en) Methods and compositions for treating hiv-related disorders
IL246587A0 (en) Compositions for use in the treatment of allergic conditions
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
IL252707B (en) Compositions and methods for treating diseases and conditions
IL252070A0 (en) Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation
IL252600A0 (en) Compositions and methods relating to proliferative disorders
GB201419559D0 (en) Therapeutic compositions and methods